Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index

Christoph Axthelm, Christian Sieder, Franziska Meister, David Pittrow, Edelgard Kaiser, Christoph Axthelm, Christian Sieder, Franziska Meister, David Pittrow, Edelgard Kaiser

Abstract

Aims: Blood pressure (BP) reduction in hypertensive patients is more difficult to achieve in the elderly or in the presence of comorbidities. We aimed to investigate the efficacy of the single-pill combination (SPC) aliskiren/amlodipine in hypertensive elderly patients, patients with high body mass index (BMI), with at least one metabolic risk factor, and/or type 2 diabetes mellitus (DM).

Methods: In an open-label non-randomized study, patients not adequately controlled by previous treatment with the SPC olmesarten 40/amlodipine 10 (phase 1) were switched to the SPC aliskiren 300/amlodipine 10 (phase 2). The present post-hoc analysis investigated BP reduction in phase 2 in the named subgroups. The EudraCT identifier was 2009-016693-33, ClinicalTrials.gov identifier NCT01113047.

Results: Of the 187 patients not adequately controlled in phase 1 and thus treated with the SPC aliskiren 300/amlodipine 10 in phase 2, 69 were of advanced age (≥65 years), 74 or 89 were overweight or obese (BMI 25.0-29.9 kg/m(2) or ≥30 kg/m(2), respectively), 91 had metabolic risk factors (without DM) and 41 had DM. At the beginning of phase 2, depending on the subgroup, baseline SBP was 168-169 mmHg and DBP 103-104 mmHg. After 4 weeks of treatment with aliskiren 300/amlodipine 10, SBP/DBP was lowered by -5.1/-4.8 mmHg in the total cohort, by -5.5/-5.1 mmHg in elderly patients, by -6.7/-5.5 in overweight and by -4.2/-4.5 mmHg in obese patients, by -6.4/-4.7 mmHg in patients with metabolic risk factors without DM, and by -3.3/-5.0 mmHg in DM patients. Limitations include low sample size, limited treatment duration and the fact that the post-hoc defined groups were not mutually exclusive.

Conclusions: In this study reflecting clinical practice, the aliskiren/amlodipine combination achieved effective BP reduction in elderly patients or with metabolic comorbidities, including DM that might be more difficult to treat. This consistent BP lowering pattern facilitates everyday care of patients who receive aliskiren/amlodipine.

Keywords: Aliskiren; Amlodipine; Arterial hypertension; Combination therapy; Diabetes mellitus; Elderly; Metabolic risk factors; Olmesartan.

Figures

Figure 1.
Figure 1.
Study design. *Visit 2 was performed only in patients with previous antihypertensive therapy. **Patients with an office mean sitting DBP

Figure 2.

Blood pressure reduction on aliskiren/amlodipine…

Figure 2.

Blood pressure reduction on aliskiren/amlodipine in the total cohort (ITT population) and in…

Figure 2.
Blood pressure reduction on aliskiren/amlodipine in the total cohort (ITT population) and in subgroups in phase 2 (week 8 compared with week 4).
Figure 2.
Figure 2.
Blood pressure reduction on aliskiren/amlodipine in the total cohort (ITT population) and in subgroups in phase 2 (week 8 compared with week 4).

References

    1. Wong ND Dede J Chow VH et al. Global cardiovascular risk associated with hypertension and extent of treatment and control according to risk group. Am J Hypertens 2012;25:561-7
    1. Dahlof B Sever PS Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
    1. Julius S Kjeldsen SE Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
    1. Ruschitzka F. Evidence for improvement in survival with antihypertensive combination treatment. J Hypertens 2011;29(Suppl 1):S9-14
    1. Mancia G De Backer G Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
    1. Chobanian AV Bakris GL Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-71
    1. Deutsche Hypertonie Gesellschaft - Deutsche Hochdruckliga e.V. (DHL). S2 Guideline: Treatment of Arterial Hypertension. Bonn, 2008. . Accessed on 27 October 2011.;34:481-98
    1. Amlodipinbesilat-Sandoz (Manufacturer: Sandoz Pharmaceuticals GmbH, Holzkirchen). Fachinformation (Prescribing Information). Update July 2010. Internet: . Accessed on 22 July 2011
    1. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995;50:560-86
    1. Bruder O Jensen C Bell M et al. Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension. J Drug Assessment 2012;1:1-10
    1. Chrysant SG Melino M Karki S et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
    1. Chrysant SG Oparil S Melino M et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009;11:475-82
    1. Barrios V Brommer P Haag U et al. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009;29:427-39
    1. Volpe M Brommer P Haag U et al. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009;29:11-25
    1. Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs 2010;70:2011-49
    1. Billecke SS, Marcovitz PA. Aliskiren/amlodipine combination for the treatment of hypertension. Drugs Today (Barc) 2011;47:403-17
    1. Black HR Weinberger MH Purkayastha D et al. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. J Clin Hypertens (Greenwich) 2011;13:571-581
    1. Palatini P Jung W Shlyakhto E et al. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010;24:93-103
    1. Dusing R Brunel P Baek I et al. Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study. J Hypertens 2012;30:1029-40
    1. Smilde J. A comparison of amlodipine and felodipine extended release in the treatment of hypertension at steady state and after two missed doses. Curr Ther Res 1997;58:141-53
    1. Brown MJ McInnes GT Papst CC et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011;377:312-20
    1. Littlejohn TW, 3rd, Jones SW, Zhang J et al. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. J Hum Hypertens 2012 (online first). Accessed on 14 January 2013
    1. Chrysant SG Murray AV Hoppe UC et al. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Curr Med Res Opin 2010;26:2841-9
    1. Glorioso N Thomas M Troffa C et al. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients with an inadequate response to aliskiren monotherapy. Curr Vasc Pharmacol 2012;10:750-7
    1. Pfeiffer D Rennie N Papst CC et al. Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy. Curr Vasc Pharmacol 2012;10:775-82
    1. European Medicines Agency (EMA). Rasilmalo (Aliskiren/Amlodipine, EMEA/H/C/002073). Summary of Product Characteristics. . Accessed on 6. October 2011
    1. Axthelm C Sieder C Meister F et al. Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg. Curr Med Res Opin 2012;28:69-78
    1. Pickering TG Hall JE Appel LJ et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45:142-61
    1. Bramlage P Pittrow D Wittchen HU et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004;17:904-10
    1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva; 1999
    1. Kerner W, Brückel J, Böhm B. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Deutsche Diabetes Gesellschaft DDG, November 2004 Herausgeber: W. A. Scherbaum, W. Kiess. Aktualisierung der 1. Auflage vom Juli 2001
    1. Einhorn D Reaven GM Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52
    1. Grundy SM Brewer HB Jr Cleeman JI et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-8
    1. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 2003;26:933-9
    1. Internation Diabetes Federation. IDF Worldwide Definition of the Metabolic Syndrome. . Accessed on 22 December 2010
    1. Jordan J Engeli S Boye SW et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047-55
    1. Schmieder RE Philipp T Guerediaga J et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009;27:1493-501
    1. Whaley-Connell A Purkayastha D Yadao A et al. Central pressure and biomarker responses to renin inhibition with hydrochlorothiazide and ramipril in obese hypertensives: The ATTAIN study. Cardiorenal Med 2011;1:53-66
    1. Braun-Dullaeus R, Shustov S, Alvarez C, et al. Aliskiren/amlodipine combination lowers BP in obese and non-obese patients with moderate-to-severe hypertension [PO-339]. Annual Meeting of the American Society of Hypertension (ASH), New York, USA, 21-24.5.2011
    1. Boschmann M Nussberger J Engeli S et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens 2012;30:561-6
    1. Krone W Hanefeld M Meyer HF et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2010;25:186-95
    1. Gradman AH Weir MR Wright M et al. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies. J Hum Hypertens 2010;24:721-9
    1. Weinberger MH Izzo JL Jr Purkayastha D et al. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. J Am Soc Hypertens 2011;5:489-97
    1. Ferdinand KC Weitzman R Purkayastha D et al. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension. J Am Soc Hypertens 2012;6:219-27
    1. Persson F Rossing P Reinhard H et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010;53:1576-80
    1. Persson F Lewis JB Lewis EJ et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 2011;6:1025-31
    1. Uresin Y Taylor AA Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8
    1. Townsend RR Forker AD Bhosekar V et al. Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2011;13:889-97
    1. Taylor A, Anderson D, Arora V, et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren in patients with diabetes: a pooled analysis of 10 randomized trials [0483-P]. Presentation at the meeting of the American Diabetes Association, June 22 - 26, 2007, Chicago, IL, USA
    1. Zeymer U, Dechend R, Deeg E, et al. Superior blood pressure reduction with aliskiren in hypertensive patients with diabetes mellitus in real life. results of the 3A registry [PP 27.364]. Annual Meeting of the European Society of Hypertension. 19 June 2011
    1. Verpooten GA Aerts A Coen N et al. Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). Int J Clin Pract 2011;65:54-63
    1. Vaidyanathan S Reynolds C Yeh CM et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007;47:453-60
    1. Villa G Le Breton S Ibram G et al. Efficacy, safety, and tolerability of aliskiren monotherapy administered with a light meal in elderly hypertensive patients: a randomized, double-blind, placebo-controlled, dose-response evaluation study. J Clin Pharmacol 2012;52:1901-11
    1. Verdecchia P Calvo C Mockel V et al. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007;16:381-91
    1. Duprez DA Munger MA Botha J et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 2010;24:600-8
    1. Schmieder R Lehmann M Dechend R et al. Blood pressure reduction in 7000 elderly hypertensive patients: results from the 3A registry. J Hypertens 2011;29(e-Supplement A):e136
    1. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004;58:635-41
    1. Wang R Lagakos SW Ware JH et al. Statistics in medicine–reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94
    1. European Agency for the Evaluation of Medicinal Products (EMA). ICH E1 Population Exposure: The Extent of Population Exposure to Assess Clinical Safety (CPMP/ICH/375/95). London, June 1995. . Accessed on 14 January 2013
    1. Weir M Prescott M Bush C et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren in patients with diabetes, metabolic syndrome or obesity: a pooled analysis of 10 randomized trials [abstract no. P888]. Circulation 2008;118:162
    1. Yarows S, Oparil S, Patel S, Wright M, Yadao A, Zhang J. Initial use of combination aliskiren/valsartan is more effective than either component monotherapy in elderly and non-elderly hypertensive patients [PO--71]. Presented at the Annual Meeting of the American Society for Hypertension 2010. J Clin Hypertens (Greenwhich) 2010;12 (Suppl. 1):A--48.
    1. Gradman A, Weir M, Arora V, et al. Aliskiren provides highly effective blood pressure reduction independent of age in patients with hypertension (p. 38). Annual Meeting of the ASH 2008. J Clin Hypertens 2008;10:A21-2
    1. Littlejohn III T, Trenkwalder P, Hollanders G, et al. Aliskiren in combination with amlodipine provides blood pressure reduction with good tolerability in hypertensive patients regardless of age over 54 weeks of treatment. Presentation at the American Society of Hypertension (ASH) 23rd Annual Scientific Meeting. May 14–17, 2008. New Orleans, Louisiana, USA. J Clin Hypertens (Greenwich) 2008;10(5 Suppl A):A1-169
    1. Basile J Babazadeh S Lillestol M et al. Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study. J Clin Hypertens (Greenwich) 2011;13:162-9
    1. Sowers J Severin T Maboudian M et al. Blood pressure lowering effects of the direct renin inhibitor aliskiren in patients with diabetes: a pooled analysis of 16 randomised trials [abstract 1106). Diabetologia 2011;54(Suppl):S1-542
    1. Braun-Dullaeus R, Zappe D, Papst C, et al. Aliskiren/amlodipine combination therapy lowers blood pressure more effectively than amlodipine alone in patients with type 2 diabetes mellitus or metabolic syndrome [PP 43.392]. Presentation at the Annual Meeting of the European Society of Hypertension (ESH).e551
    1. White W, Anderson D, Arora V, Bush C, Keefe D. Antihypertensive effectiveness of the direct renin inhibitor aliskiren in patients with metabolic syndrome: a comparative analysis of 7219 patients from 10 randomized trials [P4845]. Presentation at the Annual Meeting of the ESC September 2007, Vienna, Austria. Eur Heart J 2007;28 (Abstract Supplement):868.
    1. Lacourciere Y, Taddei S, Konis G, Salko T, Fang H, Zhang J. Aliskiren/amlodipine/hydrochlorothiazide combination lowers blood pressure more effectively than component dual combinations in moderate to severe hypertensive patients, regardless of metabolic syndrome status. Poster presentation at High Blood Pressure Research Scientific Sessions Oct 13--16, 2010. Washington, DC, USA.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel